{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Immunology & Inflammation > NepafenacCAS：78281-72-8
Molecular Formula：C15H14N2O2
Molecular Weight：254.28
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥99%
Appearance：Light yellow to yellow Solid
Qty：
Size：
| CAS | 78281-72-8 |
| Name | Nepafenac |
| Molecular Formula | C15H14N2O2 |
| Molecular Weight | 254.28 |
| Solubility | Soluble in DMSO |
| Purity | HPLC≥99% |
| Appearance | Light yellow to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD08067732 |
| SMILES | O=C(N)CC1=CC=CC(C(C2=CC=CC=C2)=O)=C1N |
| Target Point | COX |
| Passage | Immunology & Inflammation |
| Background | Nepafenac is a COX-2 inhibitor. |
| Biological Activity | Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac. IC50 value: Target: COX-2 Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery[1-5]. |
| Data Literature Source | [1]. Gamache DA，Graff G，Brady MT et al. Nepafenac，a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [2]. Ke TL，Graff G，Spellman JM，Yanni JM. Nepafenac，a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84. [3]. Lindstrom R，Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006 Feb;22(2):397-404. [4]. Marshall JC，Fernandes BF，Di Cesare S et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis. 2007 Sep;28(9):2053-8. [5]. Singh R，Alpern L，Jaffe GJ et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259-69. |
| Unit | Bottle |
| Specification | 10mg 50mg 100mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
